<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00243</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii) The start of the exposure period for the NTX measures  <!-- PJG 0012 frnewline --> study population may be staggered from that of the main study  <!-- PJG 0012 frnewline --> group to more evenly distribute the analytical work required in  <!-- PJG 0012 frnewline --> both study populations. The exposures would remain the same in  <!-- PJG 0012 frnewline --> all other respects.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Test procedures_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Animal selection_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Species and sex.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The rat is the recommended species.  <!-- PJG 0012 frnewline --> If another rodent species is used, the tester shall provide  <!-- PJG 0012 frnewline --> justification for its selection. Both sexes shall be used in any  <!-- PJG 0012 frnewline --> assessment unless it is demonstrated that one sex is refractory  <!-- PJG 0012 frnewline --> to the effects of exposure.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Age and number.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Rats shall be at least ten weeks of  <!-- PJG 0012 frnewline --> age at the beginning of the study exposure. The number of animals  <!-- PJG 0012 frnewline --> necessary for individual health effect outcomes is as follows:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (A) Thirty rodents per concentration level/group, fifteen  <!-- PJG 0012 frnewline --> of each sex, shall be used to satisfy the reporting requirements  <!-- PJG 0012 frnewline --> of the 90-day toxicity study. Ten animals per concentration  <!-- PJG 0012 frnewline --> level/group shall be designated for whole body perfusion with  <!-- PJG 0012 frnewline --> fixative (by gravity) for lung studies, and neurohistology and  <!-- PJG 0012 frnewline --> testes studies, as appropriate.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (B) Forty rodents, 25 females and ten males shall be added  <!-- PJG 0012 frnewline --> for each test concentration or control group when combining a 90-day toxicity study with a fertility assessment.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (C) The tester shall provide a group of 10 animals (five  <!-- PJG 0012 frnewline --> animals per sex per experimental/control groups) in addition to  <!-- PJG 0012 frnewline --> the main test population when performing the GFAP neurotoxicity  <!-- PJG 0012 frnewline --> HEA.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Recovery group.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The manufacturer shall include an  <!-- PJG 0012 frnewline --> group of 20 animals (10 animals per sex) in the test population,  <!-- PJG 0012 frnewline --> exposing them to the highest concentration level for the entire  <!-- PJG 0012 frnewline --> length of the study's exposure period. This group shall then be  <!-- PJG 0012 frnewline --> observed for reversibility, persistence, or delayed occurrence of  <!-- PJG 0012 frnewline --> toxic effects during a post-exposure period of not less than 28  <!-- PJG 0012 frnewline --> days.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Inhalation exposure.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i) All data developed within this study shall be in  <!-- PJG 0012 frnewline --> accordance with good laboratory practice provisions under &sect; <!-- PJG 0012 frnewline --> 79.60.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) The general conduct of this study shall be in  <!-- PJG 0012 frnewline --> accordance with the vehicle emissions inhalation exposure  <!-- PJG 0012 frnewline --> guideline in &sect;79.61.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Observation of animals. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) All toxicological (e.g., weight loss) and neurological  <!-- PJG 0012 frnewline --> signs (e.g., motor disturbance) shall be recorded frequently  <!-- PJG 0012 frnewline --> enough to observe any abnormality, and not less than weekly for  <!-- PJG 0012 frnewline --> all study animals. Animals shall be weighed weekly.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) The following is a minimal list of measures that shall  <!-- PJG 0012 frnewline --> be noted:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (A) Body weight;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (B) Subject's reactivity to general stimuli such as removal  <!-- PJG 0012 frnewline --> from the cage or handling;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (C) Description, incidence, and severity of any  <!-- PJG 0012 frnewline --> convulsions, tremors, or abnormal motor movements in the home  <!-- PJG 0012 frnewline --> cage;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (D) Descriptions and incidence of posture and gait  <!-- PJG 0012 frnewline --> abnormalities observed in the home cage;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (E) Description and incidence of any unusual or abnormal  <!-- PJG 0012 frnewline --> behaviors, excessive or repetitive actions (stereotypies),  <!-- PJG 0012 frnewline --> emaciation, dehydration, hypotonia or hypertonia, altered fur  <!-- PJG 0012 frnewline --> appearance, red or crusty deposits around the eyes, nose, or  <!-- PJG 0012 frnewline --> mouth, and any other observations that may facilitate  <!-- PJG 0012 frnewline --> interpretation of the data.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            